Sun Pharmaceutical Industries Ltd. experienced a share price drop of over 4% in early trading on Friday, following the release of its Q4 results. According to Business Upturn's report, as of 9:15 AM, shares were trading 3.53% lower at Rs 1,658.00.
The pharmaceutical company reported a revenue of ₹12,958.8 crore, marking an 8.1% increase from ₹11,982.9 crore in Q4FY24. However, this figure was below the CNBC-TV18 poll estimate of ₹13,039.2 crore, which had anticipated a 9% year-on-year rise.
Net profit disappointed analysts, reaching ₹2,153.9 crore, a 19% decrease from ₹2,658.7 crore in the previous year's quarter. Despite this, EBITDA increased by 22.4% to ₹3,715.9 crore, surpassing the projected ₹3,618 crore. The company's EBITDA margin also improved to 28.7% from 25.3% in Q4FY24, indicating enhanced operational efficiency.